参考文献: [1] J.-H. Yang, Y.-M. Chen , U. Batra, et al. Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with ...
特别提示:包括突变型EGFR抑制剂(Mutated EGFR-IN-1)在内,本公司的所有产品仅可用于科研实验,严禁用于临床医疗及其他非科研用途! 产品名称:突变型EGFR抑制剂(Mutated EGFR-IN-1) 英文名称:Mutated EGFR-IN-1 产品货
Title:Amivantamab plus lazertinib in atypical EGFR-mutated advanced non-small cell lung cancer (NSCLC): Results from CHRYSALIS-2 标题:埃万妥单抗(Amivantamab)联合拉泽替尼(Lazertinib)治疗 EGFR 非经典突变晚期非小细胞肺癌:CHRYSALIS-2 研究结果 ...
[6] Jonathan W. Goldman, Hidehito Horinouchi, Byoung Chul Cho,Jonathan W,et al.Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). ...
[8]. Rangachari D, To C, e al. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: ...
[1]AKAMATSU H, TOI Y, HAYASHI H, et al. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized ...
[2]. Ramalingam SS, et al. Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med. 2020; 382(1): 41-50.[3]. Soria JC, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(2): 113-125.[4...
[6] Jonathan W. Goldman, Hidehito Horinouchi, Byoung Chul Cho,Jonathan W,et al.Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). ASC...
研究人员表示，替雷利珠单抗单抗联合化疗已经在EGFR抑制剂治疗失败的人群中初步显示出有希望的疗效和可控的安全性。这一试验将继续进行，持续检测治疗的安全性和有效性。参考文献：[1]. Han B, Tian P, Zhao Y, et al. 148P A phase II study of tislelizumab plus chemotherapy in EGFR mutated advanced ...
[12]MINARI R, BORDI P, LA MONICA S, et al. Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC [J]. J Thorac Oncol, 2018, 13(6): e89-e91.[13]RIBEIRO M, KNEBEL F H, BETTONI ...